Imatinib: A review of its use in chronic myeloid leukaemia

Drugs

Volumn 67, Issue 2, 2007, Pages 299-320

  Moen, Marit D ^a,b   McKeage, Kate ^a,b   Plosker, Greg L ^a,b   Siddiqui, M Asif A ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANAGRELIDE; BCR ABL PROTEIN; CYTARABINE; DASATINIB; DAUNORUBICIN; DIURETIC AGENT; DRUG METABOLITE; HOMOHARRINGTONINE; HYDROXYUREA; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; NILOTINIB; RIFAMPICIN; SIMVASTATIN;

ABDOMINAL PAIN; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; BLAST CELL CRISIS; BLEEDING; BODY WEIGHT; BONE MARROW; BONE METABOLISM; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; FATIGUE; FEVER; FLUID RETENTION; FOLLOW UP; GENE MUTATION; GRANULOCYTE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOPHOSPHATEMIA; INSOMNIA; LEUKOCYTE COUNT; LOW DRUG DOSE; MINERAL METABOLISM; MORBIDITY; MORTALITY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PREDICTION; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 33847057304     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767020-00010     Document Type: Review

References (90)

1. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001 Aug; 286: 895-8
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000 Nov 15; 96 (10): 3343-56
3. Knight GW, McLellan D. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Br J Biomed Sci 2004; 61 (2): 103-11
4. Angstreich GR, Smith BD, Jones RJ. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Curr Opin Oncol 2004 Mar; 16 (2): 95-9
5. Curran MP, Croom KF, Goa KL. Imatinib mesylate: a review of its use in chronic myeloid leukemia. Am J Cancer 2003; 2 (6): 439-54
6. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63 (5): 513-22
7. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765-74
8. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 Apr 1; 105 (7): 2640-53
9. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4
10. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2 (5): 561-6
11. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15; 90: 4947-52
12. Park J, Kim S, Oh C, et al. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate. Biochem Biophys Res Commun 2005 Oct 28; 336 (3): 942-51
13. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999 Jan 20; 91 (2): 163-8
14. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295 (1): 139-45
15. Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005 May 23; 92 (10): 1881-91
16. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004 Jul 15; 104 (2): 495-501
17. Gottschalk S, Anderson N, Hainz C, et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004 Oct 1; 10 (19): 6661-8
18. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005 May; 46 (5): 540-50
19. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004 May 1; 103 (9): 3549-51
20. Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004 Jul 15; 101 (2): 332-6
21. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85
22. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002 Jul 15; 100 (2): 435-41
23. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002 Mar; 117 (3): 360-7
24. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002 Oct; 119 (1): 3-14
25. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol 2006 Mar; 13 (2): 79-86
26. 4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004 Dec 15; 104 (13): 4219-25
27. Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006 Feb 15; 107 (4): 1582-90
28. Jorgensen HG, Copland M, Allan EK, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006 Jan 15; 12 (2): 626-33
29. Aloisi A, Di Gregorio S, Stagno F, et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006 Feb 15; 107 (4): 1591-8
30. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005 Nov; 3 (6): 757-68
31. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125: 93-106
32. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 Aug 3; 293 (5531): 876-80
33. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95: 1758-66
34. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5 (1): 55-60
35. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo. Biochem Pharmacol 2003 Nov 15; 66 (10): 1907-13
36. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003 Feb; 9 (2): 625-32
37. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005 Jan; 12 (1): 33-9
38. Wang L, Knight K, Lucas C, et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006 Feb; 91 (2): 235-9
39. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004 Nov 1; 104 (9): 2926-32
40. Wang L, Pearson K, Pillitteri L, et al. Serial monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771-7
41. Martinelli G, Iacobucci I, Rosti G, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006 Mar; 17 (3): 495-502
42. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated patients with CML. Blood 2006 Jun 1; 107 (11): 4250-6. Epub 2006 Feb 7
43. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006 May 15; 12 (10): 3037-42
44. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005 Jun 20; 23 (18): 4100-9
45. Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006; 108 (1): 28-37
46. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879-94
47. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 2005; 19 (1): 77-84
48. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005 Oct; 33 (10): 1503-12
49. Novartis Pharmaceuticals Corporation. Prescribing information (US): Gleevec® (imatinib mesylate) tablets [online]. Available from URL: http://www.fda.gov/cder [Accessed 2007 Jan 16]
50. Novartis Europharm Limited. Prescribing information (EU): Glivec® (imatinib mesylate) tablets [online]. Available from URL: http://www.emea. europa.eu/humandocs/Humans/EPAR/glivec/glivec.htm [Accessed 2007 Jan 17]
51. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 Mar 1; 22 (5): 935-42
52. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003 Nov 17; 89 (10): 1855-9
53. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348 (11): 994-1004
54. Druker BJ, Guilhot F, O'Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med 2006; 355 (23): 2408-17
55. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 Mar 15; 99 (6): 1928-37
56. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 May 15; 99 (10): 3530-9
57. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346 (9): 645-52
58. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004 Nov 1; 104 (9): 2655-60
59. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006 Feb; 20 (2): 187-92
60. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004 Apr 15; 103 (8): 2873-8
61. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-postive chronic myeloid leukemia after failure of interferon-α. Blood 2003 Jul 1; 102 (1): 83-6
62. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myecoloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003 Jun 1; 21 (11): 2138-46
63. Goldman JM, Hughes T, Radich J, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study [abstract no. 163]. Blood 2005 Nov 16; 106 (11): 51a
64. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031-7
65. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract no. 23]. Blood 2004 Nov 16; 104 (11 Pt 1): 11a. Plus oral presentation presented at the 46th Annual Meeting and Exposition of the American Society of Hematology; 2004 Dec 3-7; San Diego (CA)
66. Kantarjian HM, Sawyers C, Hocchaus A, et al. Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) Chronic Myeloid Leukemia (CML) post interferon-alpha (IFN) [abstract no. 428]. Blood 2006 Nov; 108 (11): 130-1
67. Van Hoomissen IC, Hensley ML, Krahnke T, et al. Imatinib expanded access program (EAP): results of treatment in >7000 patients with chronic myeloid leukemia (CML) [abstract no. 3370]. Blood 2003 Nov 16; 102 (11 Pt 1): 906a
68. Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002 Jul; 8 (7): 2167-76
69. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006 Sep 1; 108 (5): 1478-84
70. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997 Jul 24; 337 (4): 223-9
71. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005 May 15; 103 (10): 2099-108
72. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 May 15; 99 (10): 3547-53
73. Kerkel̈a R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006 Aug; 12 (8): 908-16
74. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [letter]. Nat Med 2007 Jan; 13 (1): 13
75. Force T. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [letter]. Nat Med 2007 Jan; 13 (1): 15-6
76. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006 May 11; 354 (19): 2006-13
77. Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005; 23 (5): 515-26
78. Warren E, Ward S, Gordois A, et al. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004 Nov; 26 (11): 1924-33
79. Gordois A, Scuffham P, Warren E, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003 Aug 18; 89 (4): 634-40
80. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004 Dec 1; 101 (11): 2574-83
81. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005 Mar; 25 (3): 325-34
82. Groot MT, Anstrom KD, Reed SD, et al. Cost-effectiveness of imatinib versus interferon (IFN-α) plus low-dose cytarabine (ARA-C) for newly diagnosed chronic phase chronic myeloid leukemia (CML) in the The Netherlands [abstract no. CN3]. Value Health 2004; 7 (6): 644. Plus oral presentation presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2004 Oct 24-26; Hamburg
83. Simonsson B, Kloke O, Stahel RA. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). ESMO Guidelines Task Force. Ann Oncol 2005; 16 Suppl. 1: i52-3
84. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia v.2.2007 [online]. Available from URL: http://www.nccn.org [Accessed 2007 Jan 17]
85. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 Sep 15; 108 (6): 1809-20
86. Nadal E, Olavarria E. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. Int J Clin Pract 2004 May; 58 (5): 511-6
87. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9 (3): 271-81
88. Bristol-Myers Squibb Company. Prescribing information (US): Sprycel. (dasatinib) tablets [online]. Available from URL: https://www.sprycel.com/ [Accessed 2006 Nov 23]
89. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program) 2005, 83-7
90. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 Jun 15; 354 (24): 2542-51